Details of the Drug Combination

General Information of Drug Combination (ID: DCWICJP)

Drug Combination Name
PF-562271 PF-562271
Indication
Disease Entry Status REF
Embryonal rhabdomyosarcoma Investigative [1]
Component Drugs PF-562271   DMSLE03 PF-562271   DMSLE03
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: RD
Zero Interaction Potency (ZIP) Score: 11.68
Bliss Independence Score: 11.32
Loewe Additivity Score: 1.28
LHighest Single Agent (HSA) Score: 2.34

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PF-562271
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PF-562271 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Focal adhesion kinase 1 (FAK) TTON5IT FAK1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of PF-562271
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PF-562271 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Focal adhesion kinase 1 (FAK) TTON5IT FAK1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Diffuse intrinsic pontine glioma DC3S7F8 SU-DIPG-XIII Investigative [1]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00666926) Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms. U.S. National Institutes of Health.
3 Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.